Clinical trial NCT02624960: Safety and Performance of the AccuCinch® System
Official title: Safety and Performance of the AccuCinch® Ventricular Repair System
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Heart Failure
Mitral Valve Insufficiency
Lead sponsor: Ancora Heart, Inc.
Sponsor class: INDUSTRY
First posted: 2015-12-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-arm, multi-center, open-label controlled study that will assess the safety and performance of the Accucinch System to induce left ventricular reverse remodeling and reduce the severity of functional mitral regurgitation in symptomatic adult patients with mitral regurgitation and left ventricular remodeling due to dilated cardiomyopathy (ischemic or non-ischemic etiology), who are of high operative risk.


Eligibility criteria: Inclusion Criteria:

* Study patient is an adult of legal consent age
* Severity of FMR: ≥ Moderate
* Ejection Fraction: ≥20 to ≤60%
* Symptom Status: NYHA II-IVa
* Treatment and compliance with optimal guideline directed medical therapy for heart failure for at least 1 month
* Surgical risk: Subject is eligible for cardiac surgery

Exclusion Criteria:

* Patients with significant organic mitral valve pathology (e.g. myxomatous degeneration, mitral valve prolapse or flail leaflets)
* Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
* Prior surgical, transcatheter, or percutaneous mitral valve intervention
* Untreated clinically significant coronary artery disease requiring revascularization
* Hemodynamic instability: Hypotension or requirement for inotropic support or mechanical hemodynamic support
* Any planned cardiac surgery or interventions within the next 6 months
* NYHA class IVb (i.e., non-ambulatory) or ACC/AHA Stage D heart failure
* Fixed pulmonary artery systolic pressure \>70 mmHg
* Severe tricuspid regurgitation
* Modified Rankin Scale ≥ 4 disability
* Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
* Mitral valve area less than 4.0 cm2
* Anatomical pathology/constraints preventing appropriate access/implant of the GDS Accucinch System
* Renal insufficiency
* Mitral annular calcification
* Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis
* Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation
* Active bacterial endocarditis
* History of stroke within the prior 3 months
* Subjects in whom anticoagulation is contraindicated
* Anemia
* Thrombocytopenia or thrombocytosis
* Bleeding disorders or hypercoaguable state
* Active peptic ulcer or active gastrointestinal bleeding
* Known allergy to nitinol, polyester, or polyethylene
* Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure.
* Life expectancy \< 1 year due to non-cardiac conditions
* Currently participating in another interventional investigational study
* Implant or revision of any rhythm management device or implantable cardioverter defibrillator within the prior month
* Absence of CRT with class I indication criteria for biventricular pacing - Subjects on high dose steroids or immunosuppressant therapy
* Female subjects who are pregnant, of child bearing potential or lactating

Primary outcomes:
measure: The additive reduction in the mitral annular axial dimensions (anteroposterior plus commissure-to-commissure axes) measured via echocardiography, paired by subject
timeFrame: 6 months
Secondary outcomes:
measure: Device Success: Percentage of patients in whom all pre-specified device performance endpoints are met but no pre-specified device complications are met.
timeFrame: 30 Days, 6 months, 12 months, and 2 years
measure: Procedural Safety: Incidence rate of the occurrence of the individual pre-specified safety events that occur within 30 days of the index procedure
timeFrame: 30 days after the index procedure
measure: Long Term Safety: Incidence rate of the occurrence of the individual pre-specified safety events at 6 months, 1 year, and 2 years.
timeFrame: 6 months, 1 year, 2 years post index procedure
Other outcomes:
Locations:
Study officials:
affiliation: Medical Director, Medical Care Center Hamburg; Dept Chief, Percutaneous Treatment of Structural Heart Disease, Albertinen Heart Center, Hamburg Germany
name: Joachim Schofer, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: